Total Funding
64
64
Total FundingGrant raised
Growth Score
1 pts
Heat Score
1 pts
Company Performance Metrics
Score
Trend
AI Content may contain mistakes and is not legal, financial or investment advice.Learn more.
Growth Score - The measure of growth based on company activity, operational metrics, and investments
Growth Trend - The change in the growth score over the given time period
Heat Score - The measure of the market interest, media activity, and Crunchbase profile activity
Heat Trend - The change in the heat score over the given time period
Recent Milestones
Raised Funding Round
Jan 1, 1970
Lorem ipsum dolor sit amet, consectetur
Raised Funding Round
Jan 1, 1970
Lorem ipsum dolor sit amet, consectetur
See more interactive data and historical milestones on desktop for the best experience
34813
Seres Therapeutics is a microbiome therapeutics company that develops treatments for serious diseases.
- Geoffrey von Maltzahn: Co-Founder and CTOPast Role: Sienna Biopharmaceuticals, Co-Founder
- Carlo Tanzi: Vice President, Head of Investor Relations and Corporate Communications
About the Company
Seres Therapeutics develops and delivers therapies composed of live bacterial consortia that aim to modulate the human gut microbiome for therapeutic benefit. The company’s platform draws on insights into microbial ecology, host immune function, and gut barrier integrity to create oral treatments that act via multiple biological pathways. Its
pipeline includes products designed to prevent infectious complications and antimicrobial-resistant bloodstream infections in vulnerable patient populations, as well as treatments for inflammatory and immune-related gastrointestinal disorders. Seres translates microbiome research into clinical development, manufacture, and commercialization of these novel live biotherapeutic medicines.
